Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
526.19
+3.81 (0.73%)
At close: Sep 25, 2026, 4:00 PM EDT
527.00
+0.81 (0.15%)
After-hours: Sep 25, 2026, 7:59 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 32 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $570.32. The average 1-year stock price forecast is 8.39% higher than the current stock price, while the lowest is $350 (-33.48%) and the highest is $672 (+27.71%).
Price Target: $570.32 (+8.39%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 21 | 21 | 19 | 19 | 19 |
| Buy | 5 | 6 | 6 | 4 | 4 | 6 |
| Hold | 5 | 5 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 32 | 33 | 33 | 29 | 29 | 31 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bernstein | Bernstein | Buy Maintains $608 | Buy | Maintains | $608 | +15.55% | Sep 25, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $633 → $640 | Buy | Maintains | $633 → $640 | +21.63% | Sep 23, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $653 | Buy | Maintains | $653 | +24.10% | Sep 23, 2026 |
| UBS | UBS | Buy Maintains $585 | Buy | Maintains | $585 | +11.18% | Sep 23, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 23, 2026 |
Financial Forecast
Revenue This Year
13.25B
from 12.00B
Increased by 10.38%
Revenue Next Year
14.55B
from 13.25B
Increased by 9.81%
EPS This Year
16.17
from 18.40
Decreased by -12.12%
EPS Next Year
20.10
from 16.17
Increased by 24.29%
EPS and Forward PE are based on non-GAAP adjusted numbers.